Transition Time: CMS Deputy Slavitt Takes Over As Interim Agency Head; FDA Enters Caretaker Phase Next
This article was originally published in RPM Report
Executive Summary
Andy Slavitt will be the caretaker head of CMS for the remainder of the Obama Administration, reinforcing the focus on smooth operations and close alignment with the White House health team. Duke’s Robert Califf joins FDA as Deputy Commissioner for Medical Products just in time for that agency to enter the caretaker phase.
You may also be interested in...
Looking Forward At FDA: Hamburg’s Farewell Notes Challenges; Califf’s First Remarks Focus on Pediatrics
FDA Commissioner Margaret Hamburg is leaving the agency on a high note – and taking the opportunity to urge stakeholders to avoid the temptation to push for changes that will “”weaken or undermine” the agency. Meanwhile, FDA's new Deputy Commissioner of Medical Products Robert Califf makes his first formal remarks in that role during a stakeholder meeting on pediatric research.
Learning To Drive The ‘Chariot’: FDA Deputy Califf’s New Role
Renowned clinical trialist and cardiologist will become deputy commissioner for medical products and tobacco, a complicated and challenging position.
Expert Sparring over Xarelto: Califf and Nissen Clash
An intriguing subplot in the September 8 advisory committee review of FDA’s Xarelto review was the verbal jousting between two high-visibility figures in the world of cardiovascular drug testing and drug therapy: Robert Califf (Vice-chancellor-clinical research at Duke and a principal investigator on the key Xarelto study, ROCKET-AF) and Steve Nissen (chair-cardiovascular medicine at the Cleveland Clinic).